Skip to main content
Fig. 3 | Infectious Agents and Cancer

Fig. 3

From: Clinical impact of concurrent autologous adoptive T cells immunotherapy in active COVID-19 infected cancer patients for chemotherapy

Fig. 3

Comparison of time to relief of symptoms by patients infected with COVID-19. The ACT was able to improve mean time to symptomatic alleviation from 17.9 days and 16.88 days to 4.46 days regardless of cancer or non-cancer patients (admitted patients, n = 43; cancer patients without ACT, n = 10; admitted patients, n = 35). All data are mean ± SEM. Statistical significance was tested with one- way ANOVA

Back to article page

Infectious Agents and Cancer

ISSN: 1750-9378

Contact us